LifebankUSA Joins the Human Longevity, Inc. Family

Recently, Human Longevity, Inc. (HLI) announced the acquisition of LifebankUSA, now part of HLI’s Cellular Therapeutics business. This is exciting because we share a common vision for the future where our combined capabilities will give families peace of mind and the ability to plan for their child’s healthy life journey.

Who is HLI?

HLI is a genomics-based, technology-driven company creating the world’s largest and most comprehensive database of whole genome, phenotype and clinical data. HLI’s mission is to change the practice of medicine by making it predictive, preventative and personalized, from the beginning of life.

LifebankUSA and HLI – Better Together

LifebankUSA has proprietary stem cell banking techniques that provide high quality DNA from both mother and newborn for genome sequencing. HLI is developing a suite of newborn genome sequencing products that we will be able to offer our customers. The benefit of having newborn genome data is that families will have relevant baseline information about their child’s traits and health journey, including the risk of preventable or treatable childhood diseases, food allergies and adverse drug reactions.

Stay tuned for news on our newborn genome sequencing service. To receive updates from LifebankUSA, please click here to join our email list.